Cancer Family
Hepatobiliary Neoplasm
CI-CAN-00000198Explore in graph →
Non-malignant1,187 active trials17 approved drugs42 evidence items
- NCIt
- C8614
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000198Explore in graph →
Clinical trials
5,262 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05220722 | Pressure Enabled Delivery of SD-101 With Checkpoint Blockade for Primary Liver Tumors | terminated | Phase 1 / Phase 2 | 23 | TriSalus Life Sciences, Inc.INDUSTRY | 1 | Oct 23, 2025 | clinicaltrials |
| NCT05229601 | A Study of HFB301001 in Adult Patients With Advanced Solid Tumors | terminated | Phase 1 | 31 | HiFiBiO TherapeuticsINDUSTRY | 2 | Oct 22, 2025 | clinicaltrials |
| NCT03144661 |
| An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies |
| terminated |
| Phase 1 |
| 25 |
| Incyte CorporationINDUSTRY |
| 2 |
| Oct 21, 2025 |
| clinicaltrials |
| NCT00422877 | Taxoprexin® Treatment for Advanced Primary Cancers of the Liver, Gallbladder or Biliary Tract | terminated | Phase 2 | 13 | American Regent, Inc.INDUSTRY | 1 | Oct 16, 2025 | clinicaltrials |
| NCT04050462 | Nivolumab Combined With BMS-986253 in HCC Patients | terminated | Phase 2 | 13 | NYU Langone HealthOTHER | 1 | Oct 16, 2025 | clinicaltrials |
| NCT06302400 | Individualized Dosimetry for Holmium-166 Radioembolization in Patients With Unresectable Hepatocellular Carcinoma(RHEPaiR) | terminated | N/A | 4 | Imperial College LondonOTHER | 1 | Sep 19, 2025 | clinicaltrials |
| NCT05582018 | Safety and Effectiveness of BioTraceIO 360 for Planning, Monitoring and Assessment of Liver Tissue Ablation Procedures(PANORAMA) | terminated | N/A | 4 | Techsomed Medical Technologies LTDINDUSTRY | 1 | Sep 15, 2025 | clinicaltrials |
| NCT04502082 | Study of ET140203 T Cells in Adults With Advanced Hepatocellular Carcinoma (ARYA-1) | terminated | Phase 1 | 8 | Eureka Therapeutics Inc.INDUSTRY | 1 | Sep 8, 2025 | clinicaltrials |
| NCT05009979 | 18F-DCFPyL PET/CT in Hepatocellular Carcinoma | terminated | Phase 2 | 8 | National Cancer Institute (NCI)NIH | 1 | Aug 28, 2025 | clinicaltrials |
| NCT05451862 | Holmium-166 Transarterial Radioembolization in Unresectable, Early Stage Hepatocellular Carcinoma.(HOMIE-166) | terminated | N/A | 6 | Terumo Europe N.V.INDUSTRY | 1 | Aug 26, 2025 | clinicaltrials |
| NCT02784795 | A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors | terminated | Phase 1 | 94 | Eli Lilly and CompanyINDUSTRY | 4 | Aug 21, 2025 | clinicaltrials |
| NCT04057365 | Study of the Combination of DKN-01 and Nivolumab in Previously Treated Patients With Advanced Biliary Tract Cancer (BTC) | terminated | Phase 2 | 15 | Massachusetts General HospitalOTHER | 1 | Aug 13, 2025 | clinicaltrials |
| NCT05975645 | A Clinical Study of TQB2618 Injection Combined With Penpulimab Injection and Anlotinib Hydrochloride Capsules for First-line Treatment of Advanced Hepatocellular Carcinoma (HCC). | terminated | Phase 1 | 29 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Aug 12, 2025 | clinicaltrials |
| NCT05124743 | HLA Typing & Tumor Neoantigen Identification for Phase I/II Study of Autologous TCR-T Cells in Subjects With Solid Tumors | terminated | — | 19 | Alaunos TherapeuticsINDUSTRY | 1 | Jul 30, 2025 | clinicaltrials |
| NCT03316872 | Study of Pembrolizumab and Radiotherapy in Liver Cancer | terminated | Phase 2 | 18 | University Health Network, TorontoOTHER | 1 | Jul 25, 2025 | clinicaltrials |
| NCT07043348 | Streamlining Radioembolization for Intrahepatic Cholangiocarcinoma(ISTAR-04) | terminated | — | 1 | Seoul National University HospitalOTHER | 1 | Jul 20, 2025 | clinicaltrials |
| NCT04116320 | Focused Ultrasound Ablation and PD-1 Antibody Blockade in Advanced Solid Tumors(AM-003) | terminated | Phase 1 | 5 | Craig L Slingluff, JrOTHER | 1 | Jul 14, 2025 | clinicaltrials |
| NCT04561453 | Feasibility Study of Multi-Platform Profiling of Resected Biliary Tract Cancer | terminated | — | 14 | University of WashingtonOTHER | 1 | Jul 10, 2025 | clinicaltrials |
| NCT05563272 | 89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors(STARBURST) | terminated | Phase 2 | 11 | Telix Pharmaceuticals (Innovations) Pty LtdINDUSTRY | 1 | Jul 10, 2025 | clinicaltrials |
| NCT04520906 | To Evaluate the Safety and Efficacy of Microwave Ablation Therapy in Patients With Primary Liver Cancer | terminated | N/A | 61 | Suzhou Hengruihongyuan Medical Technology Co. LTDINDUSTRY | 1 | Jul 1, 2025 | clinicaltrials |
| NCT05432193 | FAPi Radioligand OpeN-Label, Phase 1 Study to Evaluate Safety, Tolerability and DosImetry of [Lu-177]-PNT6555; A Dose Escalation Study for TReatment of Patients With Select Solid Tumors (FRONTIER) | terminated | Phase 1 | 20 | POINT Biopharma, a wholly owned subsidiary of Eli Lilly and CompanyINDUSTRY | 2 | Jun 25, 2025 | clinicaltrials |
| NCT06370663 | First-line Treatment for Unresectable Locally Advanced Distal Cholangiocarcinoma Combining Radiotherapy and HAIC | terminated | Phase 2 | 1 | Shandong Cancer Hospital and InstituteOTHER | 1 | Jun 25, 2025 | clinicaltrials |
| NCT05630937 | Study on Safety and Efficacy of NMS-01940153E in Adult Patients With Unresectable Hepatocellular Carcinoma (HCC) Previously Treated With Systemic Therapy | terminated | Phase 1 / Phase 2 | 31 | Nerviano Medical SciencesINDUSTRY | 3 | Jun 19, 2025 | clinicaltrials |
| NCT05342350 | International Study of High-Risk Patients for Hepatocellular Carcinoma Using Liquid Biopsy(STOP-HCC) | terminated | — | 360 | Johns Hopkins UniversityOTHER | 2 | Jun 12, 2025 | clinicaltrials |
| NCT04152018 | Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors. | terminated | Phase 1 | 85 | PfizerINDUSTRY | 5 | May 28, 2025 | clinicaltrials |
| NCT03534141 | Mild Hypothermia and Acute Kidney Injury in Liver Transplantation(MHALT) | terminated | N/A | 175 | University of California, San FranciscoOTHER | 1 | May 16, 2025 | clinicaltrials |
| NCT02807181 | SIRT Followed by CIS-GEM Chemotherapy Versus CIS-GEM Chemotherapy Alone as 1st Line Treatment of Patients With Unresectable Intrahepatic Cholangiocarcinoma(SIRCCA) | terminated | Phase 2 / Phase 3 | 89 | Sirtex MedicalINDUSTRY | 8 | May 9, 2025 | clinicaltrials |
| NCT05242822 | A Study to Evaluate KIN-3248 in Participants With Advanced Tumors Harboring FGFR2 and//or FGFR3 Gene Alterations | terminated | Phase 1 | 54 | Kinnate BiopharmaINDUSTRY | 6 | May 7, 2025 | clinicaltrials |
| NCT05757492 | Study to Evaluate Safety and PK of CHS-006 in Combination With Toripalimab in Patients With Advanced Solid Tumors | terminated | Phase 1 | 22 | Coherus Oncology, Inc.INDUSTRY | 1 | May 1, 2025 | clinicaltrials |
| NCT05448677 | Ezurpimtrostat Autophagy Inhibitor in Association With Atezolizumab-Bevacizumab in First Line Treatment of Unresectable Hepatocellular Carcinoma(ABE-LIVER) | terminated | Phase 2 | 3 | University Hospital, GrenobleOTHER | 1 | Apr 20, 2025 | clinicaltrials |
| NCT05565794 | Pemigatinib After Curative Local Therapy in Advanced iCCA With FGFR2 Fusion/Rearrangements | terminated | Phase 2 | 2 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestOTHER | 1 | Apr 13, 2025 | clinicaltrials |
| NCT04383210 | Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors | terminated | Phase 2 | 54 | Elevation OncologyINDUSTRY | 4 | Apr 3, 2025 | clinicaltrials |
| NCT03829501 | A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab (KY1044) as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies | terminated | Phase 1 / Phase 2 | 222 | Kymab LimitedINDUSTRY | 6 | Apr 2, 2025 | clinicaltrials |
| NCT03889093 | Radioembolization of Primary and Secondary Liver Malignancies and The Effect On The Immune System | terminated | N/A | 14 | University of MinnesotaOTHER | 1 | Mar 24, 2025 | clinicaltrials |
| NCT04866836 | A Study of Tislelizumab Combined With Radiotherapy as the Second-line Treatment of Advanced Biliary Malignant Tumors | terminated | Phase 2 | 20 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Mar 21, 2025 | clinicaltrials |
| NCT04629339 | Study of INCB086550 in Select Solid Tumors | terminated | Phase 2 | 16 | Incyte CorporationINDUSTRY | 5 | Mar 13, 2025 | clinicaltrials |
| NCT05137899 | Neoadjuvant Combination of Atezolizumab/Bevacizumab Versus Neoadjuvant Radiation Therapy(ADVANCE HCC) | terminated | Phase 2 | 1 | Ontario Clinical Oncology Group (OCOG)OTHER | 1 | Mar 11, 2025 | clinicaltrials |
| NCT05770882 | Chidamide + Regorafenib in Hepatocellular Carcinoma (HCC) | terminated | Phase 1 / Phase 2 | 7 | Great Novel Therapeutics Biotech & Medicals CorporationINDUSTRY | 1 | Mar 11, 2025 | clinicaltrials |
| NCT03812289 | Stereotactic Body Radiation Therapy in Treating Patients With Liver Cancer | terminated | N/A | 9 | OHSU Knight Cancer InstituteOTHER | 1 | Mar 7, 2025 | clinicaltrials |
| NCT06848556 | Evaluate the Effect of Tirazamine on Primary Liver Cancer. | terminated | Phase 1 / Phase 2 | 16 | Zhejiang Raygene Pharmaceuticals Co., LtdINDUSTRY | 1 | Feb 27, 2025 | clinicaltrials |
| NCT04709380 | Phase III RCT of Radiotherapy Plus Toripalimab Versus Sorafenib in Advanced Hepatocellular Carcinoma With PVTT | terminated | Phase 3 | 36 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Feb 26, 2025 | clinicaltrials |
| NCT00051532 | Seocalcitol Versus Placebo in Advanced Hepatocellular Carcinoma | terminated | N/A | 700 | LEO PharmaINDUSTRY | 5 | Feb 25, 2025 | clinicaltrials |
| NCT00051545 | Seocalcitol Versus Placebo in the Adjuvant Treatment of Hepatocellular Carcinoma | terminated | Phase 3 | 608 | LEO PharmaINDUSTRY | 5 | Feb 25, 2025 | clinicaltrials |
| NCT05909995 | Interventional Study of INCB 99280 With Ipilimumab in Participants With Select Solid Tumors | terminated | Phase 1 | 8 | Incyte CorporationINDUSTRY | 3 | Feb 18, 2025 | clinicaltrials |
| NCT01205828 | ABT-888 and Temozolomide for Liver Cancer | terminated | Phase 2 | 16 | Georgetown UniversityOTHER | 1 | Feb 12, 2025 | clinicaltrials |
| NCT05497453 | A Phase 1/2 Study to Evaluate OTX-2002 in Patients with Hepatocellular Carcinoma and Other Solid Tumor Types Known for Association with the MYC Oncogene(MYCHELANGELO I) | terminated | Phase 1 / Phase 2 | 24 | Omega TherapeuticsINDUSTRY | 5 | Feb 3, 2025 | clinicaltrials |
| NCT05845502 | Single-arm, Open-label Clinical Study of SZ003 in the Treatment of Advanced Hepatocellular Carcinoma | terminated | N/A | 8 | Shantou University Medical CollegeOTHER | 1 | Jan 29, 2025 | clinicaltrials |
| NCT05776875 | Atezolizumab and Bevacizumab in Combination With TACE for Patients With BCLC B HCC | terminated | Phase 2 | 3 | Yale UniversityOTHER | 1 | Jan 15, 2025 | clinicaltrials |
| NCT04066660 | Study of Oligo-Fucoidan in Advanced Hepatocellular Carcinoma (HCC) | terminated | N/A | 87 | Hi-Q Marine Biotech International, Ltd.INDUSTRY | 1 | Jan 13, 2025 | clinicaltrials |
Data updated 22 days agoSource updated Oct 23, 2025source: clinicaltrials